UBS Group
SANA icon

UBS Group’s Sana Biotechnology SANA Stock Holding History

UBS Group’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.7M Sell
1,061,441
-293,848
-22% -$947K ﹤0.01% 4476
2026
Q1 		$3.9M Buy
1,355,289
+172,331
+15% +$679K ﹤0.01% 4327
2025
Q4 		$4.81M Sell
1,182,958
-261,028
-18% -$1.17M ﹤0.01% 4068
2025
Q3 		$5.13M Buy
1,443,986
+298,551
+26% +$1.08M ﹤0.01% 4010
2025
Q2 		$3.13M Buy
1,145,435
+416,613
+57% +$860K ﹤0.01% 4353
2025
Q1 		$1.22M Buy
728,822
+279,969
+62% +$783K ﹤0.01% 5110
2024
Q4 		$732K Buy
448,853
+144,115
+47% +$430K ﹤0.01% 5565
2024
Q3 		$1.27M Buy
304,738
+64,100
+27% +$337K ﹤0.01% 4430
2024
Q2 		$1.31M Sell
240,638
-133,089
-36% -$1.06M ﹤0.01% 4163
2024
Q1 		$3.74M Buy
373,727
+66,307
+22% +$497K ﹤0.01% 3284
2023
Q4 		$1.25M Buy
307,420
+199,080
+184% +$733K ﹤0.01% 4299
2023
Q3 		$419K Sell
108,340
-39,050
-26% -$210K ﹤0.01% 4793
2023
Q2 		$878K Sell
147,390
-15,653
-10% -$90.2K ﹤0.01% 4361
2023
Q1 		$533K Sell
163,043
-178,831
-52% -$715K ﹤0.01% 4634
2022
Q4 		$1.35M Buy
341,874
+282,041
+471% +$1.38M ﹤0.01% 3780
2022
Q3 		$359K Sell
59,833
-167,166
-74% -$1.21M ﹤0.01% 4622
2022
Q2 		$1.46M Sell
226,999
-80,812
-26% -$515K ﹤0.01% 3403
2022
Q1 		$2.54M Buy
307,811
+196,844
+177% +$1.59M ﹤0.01% 3202
2021
Q4 		$1.72M Buy
110,967
+55,962
+102% +$1.08M ﹤0.01% 3873
2021
Q3 		$1.24M Buy
55,005
+46,367
+537% +$973K ﹤0.01% 4000
2021
Q2 		$170K Buy
8,638
+4,086
+90% +$92.6K ﹤0.01% 5475
2021
Q1 		$153K Buy
+4,552
New +$148K ﹤0.01% 5650

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

UBS Group's SANA Position: Q2 2026 in Review

UBS Group reduced its Sana Biotechnology (SANA) stake by 22% in Q2 2026, selling an estimated $947K and leaving 1,061,441 shares worth $3.7M. The position accounts for ﹤0.01% of the portfolio, ranked #4476.

UBS Group first reported a position in SANA in Q1 2021 and has held it in 22 quarters since. The position peaked at $5.13M in Q3 2025. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • UBS Group held 1,061,441 shares of Sana Biotechnology worth $3.7M as of Q2 2026.
  • UBS Group sold 293,848 Sana Biotechnology shares in Q2 2026, an estimated $947K.
  • Sana Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4476 holding.
  • UBS Group first reported a position in Sana Biotechnology in Q1 2021 and has held it in 22 quarters since.
  • UBS Group's Sana Biotechnology position peaked at $5.13M in Q3 2025.
  • 211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.